By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Panelists discuss Eli Lilly's (LLY) Mounjaro growth, with India sales resilience but limited revenue impact. Valuation at 38x forward P/E embeds high expectations, facing risks from patent cliffs, generic competition, and payer negotiations. Next-gen candidates and manufacturing capacity are potential differentiators.
Risk: Potential patent cliffs in 2027-2028 and intense competition from generics and oral formulations from Novo Nordisk (NVO).
Opportunity: Successful next-generation oral candidates extending IP exclusivity and significant manufacturing capacity expansion.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Eli Lilly just reported strong results for a next-generation GLP-1 drug that it is developing.
GLP-1 developments in India aren't headline-grabbing news, but they are just as important to understand.
As Novo Nordisk challenges Eli Lilly's GLP-1 dominance, consumers are showing that Eli Lilly hasn't lost its edge.
The introduction of GLP-1 drugs has revolutionized the way the world looks at weight loss. Taking a shot or a pill to curb one's appetite and lose weight is close to a miracle for those who have long struggled with their weight. And, beyond aesthetics, there are significant health benefits associated with weight loss.
No wonder the competition is so fierce in the GLP-1 race. Novo Nordisk (NYSE: NVO) got a head start with Wegovy. But Eli Lilly (NYSE: LLY) quickly took over the lead position with its Mounjaro and Zepbound GLP-1 drugs. There's been a lot of news in the niche in 2026, but this lesser-known fact about Eli Lilly's Mounjaro could be more important than you think.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The biggest GLP-1 story heading into 2026 was Novo Nordisk's introduction of a GLP-1 pill. Up until that pill was introduced, the only option for consumers was to take a shot. People generally don't like shots, so there was a real opportunity for Novo Nordisk to gain back share from its main pharmaceutical competitor in the space, Eli Lilly. However, that opportunity was relatively short-lived, as Eli Lilly has now begun selling its own GLP-1 pill.
There are some nuances to consider here. Novo Nordisk's pill is basically the same drug as its shot. Eli Lilly's pill is a different drug from its shots, and it appears to be less effective than its shots. So Novo Nordisk still has a potential wedge to use against Eli Lilly in the GLP-1 race.
But Eli Lilly has a new GLP-1 drug in development that appears like it could be more effective than the current drugs on the market. That includes Eli Lilly's own Mounjaro and Zepbound. That said, this drug isn't yet on the market, so the competition between Novo Nordisk and Eli Lilly on the pill side will remain the main attraction for a little longer.
While pills are the headline grabber, investors shouldn't forget about GLP-1 shots just yet. For example, Mounjaro and Zepbound continue to produce very strong growth for Eli Lilly, with sales up 125% and 80%, respectively, in the first quarter of 2026. But there's an even more interesting stat from India.
Novo Nordisk's Wegovy just lost patent protection in India, and low-cost generics have flooded onto the scene. That's normal, but Eli Lilly still grew its Mounjaro sales by 10% in the Indian market despite cheaper GLP-1 alternatives being available. Morgan Stanley, for one, thinks this is a big story that investors are missing.
Amid all of the noise in the GLP-1 race, Eli Lilly has built a large and resilient business outside the United States. But investors are mostly focused on its U.S. business. Meanwhile, the company has quietly strung together a year of outperformance on the international GLP-1 front.
Morgan Stanley estimates that Eli Lilly controls slightly over 50% of the international market at this point. That's likely driven by Mounjaro's stronger weight-loss results compared to Wegovy. Since Novo Nordisk's Wegovy pill doesn't close that gap, Eli Lilly could continue to see strong international growth as consumers seek the most effective weight-loss options. That's the big takeaway from what is happening in India as generic versions of Wegovy roll out. If Morgan Stanley is right in its optimism, Wall Street could be underestimating Eli Lilly's growth potential.
There's just one problem with Eli Lilly that investors have to consider: valuation. The stock's price-to-earnings ratio is roughly 38x, so it won't likely interest value investors. However, that is down from the five-year average of 56x. More aggressive growth investors may want to dig into the GLP-1 events unfolding in India and also reconsider Eli Lilly's long-term international opportunity. Indeed, Morgan Stanley thinks the market is missing something big, which could mean even stronger results than are currently reflected in the stock's valuation.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $477,813! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,320,088!
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 25, 2026. *
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"India's modest Mounjaro resilience is real but too small to justify re-rating LLY above current 38x forward earnings."
The article highlights Mounjaro's 10% India sales growth despite Wegovy generics as proof of Eli Lilly's international edge, with Morgan Stanley noting over 50% global ex-US share. Yet this overlooks that India remains a tiny revenue slice versus the US, where pricing power faces Medicare negotiations and potential 2027-2028 patent cliffs. The 38x P/E already embeds strong GLP-1 expectations; sustained outperformance requires the next-gen candidate to beat Mounjaro efficacy without eroding margins on the pill version. Investors fixated on headlines may miss how quickly Novo Nordisk's oral formulation could stabilize share.
India's 10% growth could prove a leading indicator of durable brand preference that scales to larger emerging markets, pushing LLY's multiple back toward its 56x five-year average if Q2 confirms the trend.
"Eli Lilly's international GLP-1 resilience is real but represents a narrow moat against generics rather than a structural competitive advantage, and the stock's 38x P/E already prices in years of flawless execution."
The article conflates two separate dynamics: Mounjaro's domestic dominance (125% YoY growth Q1 2026) and international resilience in India (10% growth despite generic Wegovy competition). The India story is genuinely interesting—Mounjaro holding share against generics suggests either superior efficacy perception or distribution moat. However, the article doesn't quantify India's revenue contribution to LLY's total GLP-1 business, making it unclear whether 50% international market share translates to material earnings accretion. At 38x forward P/E, the stock prices in near-perfect execution across three fronts: sustained domestic dominance, international expansion, and next-gen pipeline success. The valuation compression from 56x five-year average masks that LLY still trades at a 2x premium to pharma peers despite facing real competitive pressure from NVO's oral formulation.
If Mounjaro's efficacy advantage narrows as NVO's pill matures, or if international generics pressure accelerates beyond India, the 38x multiple becomes indefensible—especially if domestic growth decelerates from 125% (which is mathematically unsustainable). The article also ignores that GLP-1 adoption curves are front-loaded; the 'resilient international business' could simply be early-cycle strength before saturation.
"Eli Lilly's current valuation assumes perpetual pricing power, ignoring the inevitable margin erosion as manufacturing capacity scales and generic competition enters the broader global market."
The article's focus on India is a classic case of 'noise as signal.' While 10% growth in India is nice, it is a rounding error compared to the U.S. market, where Eli Lilly (LLY) faces massive supply chain constraints and margin compression risks from PBM (Pharmacy Benefit Manager) negotiations. At a 38x forward P/E, the market is pricing in perfection. The real risk isn't Novo Nordisk (NVO) winning on pills; it's the potential for Medicare price negotiations and the 'cliff' that occurs when manufacturing capacity finally meets demand, forcing a shift from a supply-constrained environment to a competitive pricing environment. LLY is currently priced for a monopoly, not a commodity-adjacent pharmaceutical market.
If LLY’s next-gen oral GLP-1s prove significantly more effective than current iterations, they could render the entire 'price competition' argument moot by capturing the high-end, convenience-focused market segment entirely.
"Sustained international GLP-1 demand and pricing power are the key swing factor; if growth slows or pricing pressure intensifies, Lilly's high valuation may not be justified."
The article frames Lilly as a growth story powered by Mounjaro's superior GLP-1 profile and outsized international momentum, with Morgan Stanley estimating Lilly controls ~50% of the international GLP-1 market and India showing resilience despite cheaper generics. Lilly trades around 38x forward earnings, well above its 5-year average, implying high conviction. Key support is international expansion and potential long runway for GLP-1 adoption. However, upside depends on durable demand, favorable pricing, and minimal safety/regulatory shocks as competition intensifies—Novo’s Wegovy pill, newer GLP-1s, and payer constraints could temper growth. Any unexpected slowdown or pipeline risk could curb the multiple.
The strongest counter: international growth may be slower than hoped as generics and payer pressure bite, and Lilly's advantage could erode once Novo accelerates its pill strategy and newer GLP-1s hit the market. If the market saturates or safety concerns emerge, the stock multiple could compress.
"Next-gen IP extensions could push protection past 2030, making the 38x multiple defensible despite cliffs."
Grok flags the 2027-2028 patent cliffs but overlooks how LLY's next-gen oral candidates could secure fresh IP extending exclusivity into the 2030s across major markets. This directly undercuts the valuation compression risk Claude and Gemini both emphasize. If those filings succeed, the 38x multiple embeds realistic runway rather than perfection, even as India-style generic pressure spreads and Medicare talks intensify.
"LLY's valuation rests on pipeline speculation while facing concrete near-term margin headwinds from generics and payers that the article glosses over."
Grok's IP extension thesis assumes successful filings, but the article provides zero evidence LLY's next-gen orals have filed or cleared regulatory hurdles. Meanwhile, NVO's Wegovy pill already exists in market. Betting valuation on unfiled candidates while dismissing near-term generic/payer pressure as manageable feels backwards. The 2027-2028 cliff isn't hypothetical; the IP runway extension is.
"The true competitive advantage for LLY is not just the drug molecule, but the insurmountable scale of their global manufacturing infrastructure."
Claude is right to challenge the IP extension thesis, but everyone is ignoring the 'manufacturing moat.' LLY’s current valuation isn't just about efficacy; it reflects a massive, multi-billion dollar capital expenditure in site capacity that NVO cannot replicate overnight. While you all debate pills and cliffs, the real risk is the 'cold chain' and sterile fill-finish bottlenecks. Whoever solves the global supply chain at scale wins the market share, regardless of minor efficacy deltas or patent expiration dates.
"Supply capacity alone won't sustain margins; payer dynamics and real-world adherence matter more than bottlenecks."
Gemini, I’d push back on assuming capacity wins on its own. Both Lilly and Novo are expanding plants; a supply moat only matters if demand stays robust and pricing holds. The bigger risk is payer dynamics and real-world adherence: even with scale, if patients abandon injections or step therapy narrows reimbursement, margins erode faster than capacity can fill. Bottlenecks matter, but pricing discipline and uptake drive true level profits.
Panelists discuss Eli Lilly's (LLY) Mounjaro growth, with India sales resilience but limited revenue impact. Valuation at 38x forward P/E embeds high expectations, facing risks from patent cliffs, generic competition, and payer negotiations. Next-gen candidates and manufacturing capacity are potential differentiators.
Successful next-generation oral candidates extending IP exclusivity and significant manufacturing capacity expansion.
Potential patent cliffs in 2027-2028 and intense competition from generics and oral formulations from Novo Nordisk (NVO).